HDAC9 and nonpapillary renal cell carcinoma: In ccRCC, our lab has previously shown that the class I HDAC inhibitor, Entinostat, enhances immunotherapy [38] and another study demonstrated synergistic anti-proliferative effects of the combination of sorafenib with HDAC inhibitors [39].